EMBC Embecta Corp.
USHealthcareAs of 2026-07-09 12:11
Why EMBC matters now
Embecta Corp. (EMBC) is a US stock in Healthcare. The latest InvestLog snapshot shows $3.15 with -1.41% on the session and $186.6M in market capitalization; recent performance reads 1-month +7.24% and YTD -73.82%.
The latest financial table shown here is Q2 2026, with revenue of $221.8M, net income of $-4.1M, and EPS of $-0.07. Investors can compare that operating picture with valuation signals such as P/E 3.76 and FCF yield 110.9%.
The latest indexable market news headline is "EMBC SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Embecta Investors of Securities Class Action Lawsuit Deadline on August 17, 2026" from Newsfile Corp.
Additional event context on this page matters because analyst consensus is Hold with a median target of $5.00; recent insider activity includes Roth Anthony M. filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
3.76
PEG
0.03
P/B
-0.29
P/S
0.18
EV/EBITDA
4.21
DCF Value
$41.34
FCF Yield
110.9%
Div Yield
14.8%
Margins & Returns
Gross Margin
62.5%
Operating Margin
29.8%
Net Margin
10.7%
ROE
-17.5%
ROA
10.9%
ROIC
25.8%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2026 | $221.8M | $-4.1M | $-0.07 |
| Q1 2026 | $261.2M | $44.1M | $0.74 |
| Q4 2025 | $264.0M | $26.4M | $0.45 |
| FY 2025 | $1.08B | $95.4M | $1.62 |
Analyst Ratings
Consensus
Hold
Target (Consensus)
$5.00
Target (Median)
$5.00
Target Range
$5.00 - $5.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Country
US
Exchange
—
Beta
0.81
Embecta Corp. is a medical technology enterprise devoted to enhancing the quality of life and health outcomes for individuals living with diabetes. Its comprehensive product portfolio includes essential tools such as pen needles, syringes, and advanced safety devices. Additionally, the company provides innovative digital applications designed to support patients in effectively managing their condition. Embecta distributes its offerings primarily through a network of wholesalers and distributors, reaching markets both domestically within the United States and across the globe. Established in 1924, Embecta's headquarters are located in Parsippany, New Jersey. The company transitioned to an independent entity from Becton, Dickinson and Company on April 1, 2022.